NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

Core Insights - NewcelX Ltd. has appointed Prof. Jeremy Shefner to its Scientific Advisory Board, enhancing its expertise in ALS and neuromuscular disorders [1][4]. Company Overview - NewcelX Ltd. is a clinical-stage biotechnology company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases [1][4]. - The company integrates advanced stem-cell technologies with neuroscience to create scalable treatments for conditions like ALS and Type 1 Diabetes [4]. Appointment of Prof. Jeremy Shefner - Prof. Shefner is a prominent neurologist with a specialization in ALS and neuromuscular disorders, serving as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute [2][3]. - He has co-founded the Northeast ALS Clinical Trials Consortium and has published over 200 peer-reviewed papers on ALS [2]. Strategic Role - In his role on the SAB, Prof. Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development of AstroRx® [3]. - His expertise will support the integration of neuromuscular and neurodegenerative disease knowledge into NewcelX's broader therapeutic platform [3]. Leadership Comments - Ronen Twito, Executive Chairman & CEO of NewcelX, expressed confidence that Prof. Shefner's leadership in ALS research will enhance the company's ability to deliver advanced therapies [4]. - Prof. Shefner highlighted the potential of NewcelX's integrated approach to address ALS and other neurodegenerative diseases [4].